sElective Serotonin Reuptake Inhibitors for post-covid: ESPRIT
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 11080022420014
Grant search
Key facts
Disease
COVID-19Start & end year
20242026Known Financial Commitments (USD)
$0Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
dr. PT (Pythia) NieuwkerkResearch Location
NetherlandsLead Research Institution
Amsterdam UMC Locatie AMCResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Post acute and long term health consequencesSpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common disabling complaints after a COVID-19 infection. The pathophysiology (mechanisms leading to disruption) of post-COVID is largely unknown and there is no established biomedical treatment. A promising candidate intervention is treatment with the selective serotonin reuptake inhibitor (SSRI) fluvoxamine, which may reduce post-COVID complaints through a regulating effect on the (neuro) immune system, the hypothalamic-pituitary-adrenal gland (HPA) and the tryptophan system.